iShares US Pharmaceuticals ETF
127 hedge funds and large institutions have $127M invested in iShares US Pharmaceuticals ETF in 2023 Q1 according to their latest regulatory filings, with 15 funds opening new positions, 34 increasing their positions, 29 reducing their positions, and 18 closing their positions.
17% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 29
2.23% more ownership
Funds ownership: 100.23% → 102.46% (+2.2%)
2% less funds holding
Funds holding: 130 → 127 (-3)
9% less capital invested
Capital invested by funds: $140M → $127M (-$13.2M)
17% less first-time investments, than exits
New positions opened: 15 | Existing positions closed: 18
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RIG
RiverFront Investment Group
Richmond,
Virginia
|
+$5.81M |
| 2 |
RJA
Raymond James & Associates
St Petersburg,
Florida
|
+$4.4M |
| 3 |
Envestnet Asset Management
Chicago,
Illinois
|
+$3.92M |
| 4 |
Jane Street
New York
|
+$2.42M |
| 5 |
Janney Montgomery Scott
Philadelphia,
Pennsylvania
|
+$1.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Wells Fargo
San Francisco,
California
|
-$8.47M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$5.52M |
| 3 |
RWP
RWA Wealth Partners
Newton,
Massachusetts
|
-$3.73M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$3.71M |
| 5 |
Morgan Stanley
New York
|
-$1.75M |
IHE Hedge Fund Activity: Q1 2023 in Review
127 of the 6,275 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q1 2023, worth a combined $127M — down 9.4% from $140M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of IHE and 15 opened new positions — a net loss of 3 holders — while 29 trimmed existing stakes and 34 added.
The largest buyer was RiverFront Investment Group, opening a new position worth an estimated $5.81M. The largest seller was Wells Fargo, cutting an estimated $8.47M.
- 127 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q1 2023, down from 130 in Q4 2022.
- Funds reported $127M of iShares US Pharmaceuticals ETF stock for Q1 2023, down 9.4% quarter-over-quarter.
- 15 funds opened new iShares US Pharmaceuticals ETF positions in Q1 2023 and 18 closed out, a net change of -3 holders.
- The largest iShares US Pharmaceuticals ETF buyer in Q1 2023 was RiverFront Investment Group, an estimated $5.81M added.
- The largest iShares US Pharmaceuticals ETF seller in Q1 2023 was Wells Fargo, an estimated $8.47M sold.
Based on aggregated 13F filings for Q1 2023.